灯盏花苷Ⅰ及其衍生物结构与生物活性关系的ab initio计算

Ab initio Calculation for the Relationship between Structure and Bioactivity of Erigeside I and Its Derivatives

采用ab initio量子化学方法和定量构效关系(QSAR)研究等理论方法,对灯盏花苷Ⅰ及其衍生物的结构和生物活性的关系进行了探讨.在6-31G水平上,量子化学从头算和QSAR的计算结果表明:当灯盏花苷Ⅰ及其衍生物作用于受体上的时候,其糖体部分是反应的活性中心,而且最高占据轨道与最低空轨道的能量差ΔE(H-L)、第5个碳原子的电荷Q(C5)是影响药物活性的主要因素.计算得到了其药物的构效关系的方程式为:pIC50=-34·525-295·481Q(C5)-805·09[Q(C5)]2+55.876[ΔE(H-L)]2+1·233EL2该方程为类似衍生物生物活性的预测提供了一个简单可行的方法.

In this paper, theoretical methods including QSAR and ab initio quantum chemistry calculations are used to elucidate the relationship between the structure and the bioactivity of the erigeside Ⅰ （ 1-0-[3-（4H-pyranoneyl） ]6-0-caffeoyl-β-D- ghcopyranoside）and its derivatives. It is shown through the ab initio calculation at 6-31 （; level that the glycosyl-body parts are the active center of reactions when the erigeside Ⅰ and its derivatives act on the receptors, and that the AE（H-L） and the charge of Q（ C5 ） are principal elements which affect the ac- tivity of the drugs. The QSAR equations is obtained as follows：pIC50=-34.525-295.481Q（C5）-805.09[Q（C5）]^2＋55.876[△E（H-L）^2]＋1.233EL^2 It provides a simple and feasible method to forecast the activity of similar derivatives.